P
Peder L. Myhre
Researcher at Akershus University Hospital
Publications - 88
Citations - 1243
Peder L. Myhre is an academic researcher from Akershus University Hospital. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 12, co-authored 57 publications receiving 581 citations. Previous affiliations of Peder L. Myhre include Harvard University & Oslo University Hospital.
Papers
More filters
Journal ArticleDOI
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.
Are A Kalstad,Are A Kalstad,Peder L. Myhre,Peder L. Myhre,Kristian Laake,Sjur H Tveit,Sjur H Tveit,Erik Berg Schmidt,Paal Smith,Paal Smith,Dennis W.T. Nilsen,Dennis W.T. Nilsen,Arnljot Tveit,Arnljot Tveit,Morten W. Fagerland,Svein Solheim,Ingebjørg Seljeflot,Ingebjørg Seljeflot,Harald Arnesen,Harald Arnesen,Omemi Investigators +20 more
TL;DR: The hypothesis was that daily addition of 1.8g n-3 PUFA to standard of care secondary prophylaxis in elderly patients who have survived an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up.
Journal ArticleDOI
B-type natriuretic peptide during treatment with sacubitril/valsartan: the paradigm-hf trial
Peder L. Myhre,Muthiah Vaduganathan,Brian Claggett,Milton Packer,Akshay S. Desai,Jean L. Rouleau,Michael R. Zile,Karl Swedberg,Martin Lefkowitz,Victor Shi,John J.V. McMurray,Scott D. Solomon +11 more
TL;DR: Circulating levels of BNP may increase meaningfully early after initiation of sacubitril/valsartan, and NT-proBNP is not a substrate of neprilysin inhibition, and thus may lead to less clinical confusion when measured within 8 to 10 weeks of drug initiation.
Journal ArticleDOI
Novel biomarkers of cardiovascular disease: Applications in clinical practice.
Magnus Nakrem Lyngbakken,Peder L. Myhre,Peder L. Myhre,Helge Røsjø,Helge Røsjø,Torbjørn Omland,Torbjørn Omland +6 more
TL;DR: This review will initially describe the fundamental approach to evaluate a novel biomarker, and discuss novel applications of cardiovascular biomarkers, more specifically prediction of ventricular arrhythmias, and the use of biomarkers in composite risk prediction models.
Journal ArticleDOI
Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19.
Peder L. Myhre,Peder L. Myhre,Christian Prebensen,Christian Prebensen,Heidi Strand,Ragnhild Røysland,Ragnhild Røysland,Christine M. Jonassen,Anbjørg Rangberg,Vibecke Sørensen,Signe Søvik,Signe Søvik,Helge Røsjø,Helge Røsjø,My Svensson,My Svensson,Jan Erik Berdal,Jan Erik Berdal,Torbjørn Omland,Torbjørn Omland +19 more
TL;DR: GDF-15 is elevated in the majority of patients hospitalized with COVID-19, and higher concentrations are associated with SARS-CoV-2 viremia, hypoxemia, and worse outcome.
Journal ArticleDOI
Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity
Gemma Chiva-Blanch,Gemma Chiva-Blanch,Gemma Chiva-Blanch,Kristian Laake,Kristian Laake,Peder L. Myhre,Peder L. Myhre,Vibeke Bratseth,Harald Arnesen,Harald Arnesen,Svein Solheim,Lina Badimon,Ingebjørg Seljeflot,Ingebjørg Seljeflot +13 more
TL;DR: Platelets and monocytes remain activated in AMI patients treated as per guidelines and release cMPs that discriminate AMI severity and thrombotic burden, therefore, TF-MPs, and platelet- and monocyte- MPs may reflect thromBotic burden in AMi patients.